NCT01773083

Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma

Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized Heparin Versus Placebo in Burn Patients With Inhalation Trauma (Hepburn)

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this international multi-center double-blind randomized placebo-controlled trial is to determine the effect of nebulized heparin, compared to placebo, on the number of ventilator-free days at day 28, in burn patients with confirmed inhalation trauma requiring mechanical ventilation.

Conditions

• Inhalation Injury
• Burn Injury

Interventions

Type	Name	Description
DRUG	unfractionated heparin	nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
DRUG	placebo	Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days

Timeline

• Start date: 2013-10-01
• Primary completion: 2016-10-01
• Completion: 2017-12-01
• First posted: 2013-01-23
• Last updated: 2022-02-16

Locations

8 sites across 3 countries: Australia, Belgium, Netherlands